Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

被引：0
|
作者：
Kilickap, S. [1 ]
Sezer, A. [2 ]
Gumus, M. [3 ]
Bondarenko, I. [4 ]
Ozguroglu, M. [5 ]
Gogishvili, M. [6 ]
He, X. [7 ]
Gullo, G. [7 ]
Rietschel, P. [7 ]
Quek, R. G. [7 ]
机构：
[1] Istinye Univ, Dept Med Oncol, Fac Med, Istanbul, Turkey
[2] Baskent Univ, Dept Med Oncol, Adana, Turkey
[3] Istanbul Medeniyet Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[4] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[5] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[6] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia
[7] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; patient-reported outcomes; cemiplimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-12
引用
收藏
页码：S125 / S126
页数：2
相关论文
共 50 条
  • [31] Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy
    King-Kallimanis, B. L.
    Kanapuru, B.
    Blumenthal, G. M.
    Theoret, M. R.
    Kluetz, P. G.
    SEMINARS IN ONCOLOGY, 2018, 45 (04) : 201 - 209
  • [32] Flexibility in chemotherapy regimens in first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with cemiplimab in combination with chemotherapy: analysis from EMPOWER-Lung 3
    Rosen, Jan-Paul
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Baramidze, Ana
    Zhu, Cong
    Mcintyre, Debra Ag
    Venkateshan, Satish
    Kim, Eric
    Magnan, Heather
    Pouliot, Jean -Francois
    LUNG CANCER, 2025, 200
  • [33] A Phase 2/3 Study of Fianlimab plus Cemiplimab versus Cemiplimab in Patients with Advanced NSCLC with Tumors Expressing PD-L1 ≥50%
    Faulkner, Neil
    Nair, Santosh
    Gabrail, Nashat
    Kunta, Gopal
    Ibrahim, Emad
    Dreisbach, Luke
    Brungs, Daniel
    Mani, Jayakumar
    Ghattas, Maria
    Li, Siyu
    Salvati, Mark
    Lowy, Israel
    Hiley, Tara
    Fury, Matthew G.
    Paoluzzi, Luca
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E39 - E39
  • [34] First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
    Kalinka, E.
    Bondarenko, I.
    Gogishvili, M.
    Melkadze, T.
    Baramidze, A.
    Sezer, A.
    Makharadze, T.
    Kilickap, S.
    Gumus, M.
    Penkov, K. D.
    Giorgadze, D.
    Ozguroglu, M.
    He, X.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S106 - S106
  • [35] Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
    Ozguroglu, Mustafa
    Sezer, Ahmet
    Kilickap, Saadettin
    Gumus, Mahmut
    Bondarenko, Igor
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Bentsion, Dmitry
    Gladkov, Oleg
    Clingan, Philip R.
    Sriuranpong, Virote
    Rizvi, Naiyer A.
    McGinniss, Jennifer
    Pouliot, Jean-Francois
    Lee, Sue
    Seebach, Frank A.
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Baramidze, Ana
    Giorgadze, Davit
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Li, Siyu
    Li, Yuntong
    Kaul, Manika
    Quek, Ruben G. W.
    Poulio, Jean-Francois
    Seebach, Frank
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (06) : 755 - 768
  • [37] Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
    Makharadze, T.
    Gogishvili, M.
    Melkadze, T.
    Baramidze, A.
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Penkov, K. D.
    Giorgadze, D.
    Ozguroglu, M.
    Kalinka, E.
    McIntyre, D.
    Kaul, M.
    Quek, R. G. W.
    Pouliot, J-F.
    Seebach, F.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2023, 34
  • [38] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Wang, Liting
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Li, Sini
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4354 - 4365
  • [39] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Liting Wang
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Sini Li
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 4354 - 4365
  • [40] EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer
    Oaknin, Ana
    Monk, Bradley J.
    Vergote, Ignace
    de Melo, Andreia Cristina
    Kim, Yong-Man
    Lisyanskaya, Alla S.
    Samouelian, Vanessa
    Kim, Hee Seung
    Gotovkin, Evgeniy A.
    Damian, Fernanda
    Chang, Chih-Long
    Takahashi, Shunji
    Li, Jingjin
    Mathias, Melissa
    Fury, Matthew G.
    Ivanescu, Cristina
    Reaney, Matthew
    LaFontaine, Patrick R.
    Lowy, Israel
    Harnett, James
    Chen, Chieh-, I
    Tewari, Krishnansu S.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : 299 - 309
12345